Brian Cheng
Stock Analyst at JP Morgan
(2.24)
# 2,789
Out of 5,161 analysts
75
Total ratings
43.55%
Success rate
-1.95%
Average return
Main Sectors:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARA Protara Therapeutics | Initiates: Overweight | $27 | $5.32 | +407.52% | 1 | Mar 4, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Overweight | $29 | $11.78 | +146.18% | 1 | Mar 2, 2026 | |
| TGTX TG Therapeutics | Maintains: Overweight | $49 → $46 | $26.94 | +70.75% | 1 | Feb 2, 2026 | |
| RVMD Revolution Medicines | Maintains: Overweight | $92 → $122 | $95.07 | +28.33% | 2 | Feb 2, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $70 → $125 | $77.50 | +61.29% | 1 | Dec 10, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.16 | - | 1 | Nov 20, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $68 → $81 | $95.42 | -15.11% | 6 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Underweight | $12 → $5 | $12.85 | -61.09% | 5 | Nov 7, 2025 | |
| XNCR Xencor | Maintains: Overweight | $20 → $18 | $11.61 | +55.04% | 5 | Nov 6, 2025 | |
| ZYME Zymeworks | Maintains: Overweight | $20 → $23 | $23.23 | -0.99% | 3 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.47 | - | 5 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.41 | - | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $2.30 | - | 1 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $33 | $24.99 | +32.05% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $47 | $62.97 | -25.36% | 2 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $20 | $28.55 | -29.95% | 7 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $48.87 | +43.24% | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.28 | - | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $22 | $20.99 | +4.81% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $24.00 | - | 1 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.54 | - | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $8.77 | +276.28% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.57 | +282.17% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.17 | +8,218.48% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.35 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $320 → $96 | $7.04 | +1,263.64% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.00 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.46 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $7.00 | +1,114.29% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $8.38 | +150.60% | 1 | Aug 3, 2021 |
Protara Therapeutics
Mar 4, 2026
Initiates: Overweight
Price Target: $27
Current: $5.32
Upside: +407.52%
Eikon Therapeutics
Mar 2, 2026
Initiates: Overweight
Price Target: $29
Current: $11.78
Upside: +146.18%
TG Therapeutics
Feb 2, 2026
Maintains: Overweight
Price Target: $49 → $46
Current: $26.94
Upside: +70.75%
Revolution Medicines
Feb 2, 2026
Maintains: Overweight
Price Target: $92 → $122
Current: $95.07
Upside: +28.33%
Kymera Therapeutics
Dec 10, 2025
Maintains: Overweight
Price Target: $70 → $125
Current: $77.50
Upside: +61.29%
OPKO Health
Nov 20, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.16
Upside: -
Protagonist Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $68 → $81
Current: $95.42
Upside: -15.11%
Intellia Therapeutics
Nov 7, 2025
Downgrades: Underweight
Price Target: $12 → $5
Current: $12.85
Upside: -61.09%
Xencor
Nov 6, 2025
Maintains: Overweight
Price Target: $20 → $18
Current: $11.61
Upside: +55.04%
Zymeworks
Oct 16, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $23.23
Upside: -0.99%
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $2.47
Upside: -
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.41
Upside: -
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $2.30
Upside: -
Sep 30, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $24.99
Upside: +32.05%
Sep 26, 2025
Maintains: Overweight
Price Target: $41 → $47
Current: $62.97
Upside: -25.36%
Sep 18, 2025
Maintains: Overweight
Price Target: $16 → $20
Current: $28.55
Upside: -29.95%
Sep 18, 2025
Initiates: Overweight
Price Target: $70
Current: $48.87
Upside: +43.24%
Aug 15, 2025
Upgrades: Neutral
Price Target: n/a
Current: $3.28
Upside: -
Aug 7, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $20.99
Upside: +4.81%
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $24.00
Upside: -
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $2.54
Upside: -
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $8.77
Upside: +276.28%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.57
Upside: +282.17%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.17
Upside: +8,218.48%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $4.35
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $320 → $96
Current: $7.04
Upside: +1,263.64%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $1.00
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.46
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $7.00
Upside: +1,114.29%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $8.38
Upside: +150.60%